# Intracardiac Thrombus in COVID-19 Inpatients: A Nationwide Study of Incidence, Predictors and Outcomes

Ankit Agrawal MD<sup>1\*</sup>, Suryansh Bajaj MD<sup>2\*</sup>, Umesh Bhagat MD<sup>3</sup>, Sanya Chandna MD<sup>3</sup>, Aro Daniela Arockiam MD<sup>1</sup>, Nicholas Chan MD MS<sup>1</sup>, Elio Haroun MD<sup>1</sup>, Rahul Gupta<sup>4</sup>, Osamah Badwan MD<sup>1</sup>, Shashank Shekhar MD<sup>1</sup>, Shivabalan Kathavarayan Ramu MD<sup>1</sup>, Divya Nayar MD<sup>5</sup>, Wael Jaber, MD<sup>1</sup>, Brian P Griffin, MD<sup>1</sup>, Tom Kai Ming Wang MBChB, MD<sup>1</sup>

<sup>1</sup>Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, United States

<sup>2</sup>Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas

<sup>3</sup>Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio

<sup>4</sup>Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, Pennsylvania

<sup>5</sup>Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, Arkansas

\*Authors have contributed equally to the article and to be considered as first co-authors

Short Title: Intracardiac thrombus in COVID-19 patients

Word count: 6,863

**Corresponding author:** Tom Kai Ming Wang MBChB, MD, FRACP, FACC, FESC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic 9500 Euclid Avenue, Main Campus J1-5, Cleveland Clinic, Cleveland, OH 44195, United States

NOOTIG his prebind 40% in the hose of the the total the total the total the total to a section of the total total to a section of the total tota

#### ABSTRACT

**Background:** COronaVIrus Disease 2019 (COVID-19) has been observed to be associated with a hypercoagulable state. Intracardiac thrombosis is a serious complication but has seldom been evaluated in COVID-19 patients. We assessed the incidence, associated factors, and outcomes of COVID-19 patients with intracardiac thrombosis.

**Methods:** COVID-19 inpatients during 2020 were retrospectively identified from the national inpatient sample (NIS) database, and data retrieved regarding clinical characteristics, intracardiac thrombosis, and adverse outcomes. Multivariable logistic regression was performed to identify the clinical factors associated with intracardiac thrombosis and inhospital mortality and morbidities.

**Results:** A total of 1,683,785 COVID-19 inpatients were identified in 2020 from NIS, with a mean age of  $63.8 \pm 1.6$  years, and 32.2% females. Intracardiac thrombosis was present in 0.001% (1,830) patients. Overall, in-hospital outcomes include all-cause mortality 13.2% (222,695/1,683,785), cardiovascular mortality 3.5%, cardiac arrest 2.6%, acute coronary syndrome (ACS) 4.4%, heart failure 16.1%, stroke 1.3% and acute kidney injury (AKI) 28.3%. The main factors associated with intracardiac thrombosis were a history of congestive heart failure and coagulopathy. Intracardiac thrombosis was independently associated with a higher risk of in-hospital all-cause mortality (OR: 3.32, 95% CI: 2.42-4.54, p<0.001), cardiovascular mortality (OR: 2.95, 95% CI: 1.96-4.44, p<0.001), cardiac arrest (OR: 2.04, 95% CI: 1.22-3.43, p=0.006), ACS (OR: 1.62, 95% CI: 1.17-2.22, p=0.003), stroke (OR:

3.10, 95% CI: 2.11-4.56, p<0.001), and AKI (OR: 2.13 95% CI: 1.68-2.69, p<0.001), but not incident heart failure (p=0.27).

**Conclusion:** Although intracardiac thrombosis is rare in COVID-19 inpatients, its presence was independently associated with higher risks of in-hospital mortality and most morbidities. Prompt investigations and treatments for intracardiac thrombosis are warranted when there is a high index of suspicion and a confirmed diagnosis respectively.

Keywords: COVID-19, intracardiac thrombosis, thromboembolism, mortality

## **INTRODUCTION**

COVID-19 was declared as a pandemic by the World Health Organization (WHO) in March 2020.<sup>1</sup> While the culprit virus primarily infects the respiratory tract, there is growing evidence of the multisystem involvement of the illness. Recent studies have shown that the recent strains of coronavirus promote a hypercoagulable state via abnormally elevated levels of procoagulant cytokines in circulation and virus-mediated endothelial inflammation.<sup>2,3</sup> The thrombotic sequala varies in terms of location and clinical presentation but is often associated with adverse clinical outcomes. There are a few case reports and series of intracardiac thrombosis in COVID-19 patients, many of whom with no prior history of cardiovascular disease or risk factors for coagulopathy.<sup>4,8</sup> While some studies have estimated the incidence and outcomes of arterial and venous thromboembolism in COVID-19 patients, data are lacking regarding intracardiac thrombosis in COVID-19 patients. To the best of our knowledge, this is the first large-scale nationwide study to assess the incidence of and factors associated with intracardiac thrombosis in COVID-19 patients and evaluate its association with end-organ damage and patient mortality.

#### **METHODS**

### **Study population**

The National Inpatient Sample (NIS) database 2020, managed by the Agency for Healthcare Research and Quality via Healthcare Cost and Utilization Project (HCUP),<sup>9</sup> was used for the collection of patient data. The NIS database is a collection of over 7 million inpatient data reported annually from all the participating states. Publicly available and anonymous data from the NIS website without any patient identifying features were used for our study, which precludes the requirement of Institutional Review Board approval and informed consent.

#### Study characteristics and outcomes

International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), claims codes were used to identify the patient cohort. Firstly, patients hospitalized for COVID-19 were identified using ICD-10-CM code U07.1. Amongst this patient cohort, ICD-10-CM code I51.3 was used to identify patients with concomitant intracardiac thrombosis diagnosed during hospitalization. Patients aged<18 years were excluded from our study.

The following NIS variables were used for data collection: age, sex, race, hospital type, and hospital region. Conditions such as congestive heart failure, valvular disease, pulmonary circulation disorders, peripheral vascular disorder, uncomplicated and complicated hypertension, paralysis, other neurological disorder, chronic obstructive pulmonary disorder, uncomplicated and complicated diabetes, renal failure, liver disease, lymphoma, metastatic cancer, solid tumor, acquired immune deficiency syndrome/human immunodeficiency virus, rheumatoid arthritis/collagen vascular disorder, blood loss anemia, deficiency anemia, and alcohol abuse were part of the Elixhauser comorbidity index and were utilized directly in the analysis. ICD-10-CM codes were used to identify the remaining variables. Asymptomatic COVID-19 was defined as patients with the diagnosis of COVID-19 without any related symptoms. Symptomatic COVID-19 was defined as patients with COVID-19 and acute bronchitis, lower respiratory tract infection, pneumonia, and acute respiratory distress syndrome (ARDS). Severe COVID-19 was defined as patients with COVID-19 and related severe sepsis and/or septic shock, intubation and assisted ventilation, non-invasive ventilation, use of extracorporeal membrane oxygenation, cardiac arrest, acute respiratory failure, need for hemodialysis and packed red blood cell transfusion.

The primary endpoint was intracardiac thrombosis. The secondary endpoints studied were inhospital all-cause and cardiovascular mortality and in-hospital complications, including acute kidney injury (AKI), stroke, cardiac arrest, acute coronary syndrome (ACS), and heart failure.

#### **Statistical Analyses**

Means with standard deviations (or medians with interquartile ranges) and number of individuals with proportions were calculated for continuous and categorical variables, respectively. The characteristics between those with and without intracardiac thrombosis were compared using student t-test (or Wilcoxon Rank-Sum test for non-normal distribution, with normality assessed by Shapiro-Wilk test) for continuous variables and chi-square test (or Fisher exact test) for categorical variables. Multivariate logistic regression analysis was performed to identify the risk factors for organ damage and patient mortality in the overall cohort, and with intracardiac thrombosis. All the covariates utilized are risk factors based on clinical significance from established literature. A p-value of <0.05 was considered statistically significant. The analysis was conducted using StataCorp. 2021. Stata Statistical Software: Release 17. StataCorp LLC (College station, TX, USA). Stata's every command and appropriate weights were used in all estimations.

#### RESULTS

#### **Baseline characteristics**

A total of 1,683,875 patients who tested positive for COVID-19 in the year 2020 were identified, out of which, 1,830 patients were found to have intracardiac thrombosis. The incidence was 0.001% with a mean age of  $63.8 \pm 1.6$  years and 32.2% females. Demographic and clinical characteristics of COVID-19 patients with and without intracardiac thrombosis are compared and described in Table 1.Compared to COVID patients without intracardiac thrombosis, those with thrombosis were more likely to be men (67.8% vs.52%, p<0.001),

African Americans (31.5% vs 19%, p<0.001), have a longer median length of stay in the hospital (8 (4-14) vs.5 (3-10) days), be asymptomatic (34.5% vs. 24.8%. p<0.001), and admitted to large (58% vs. 46.8%, p<0.001) urban teaching hospitals (84.4% vs. 71.8%, p<0.001). The in-hospital all-cause mortality and cardiovascular mortality in the overall cohort were 13.2% (222,695/1,683,785) and 3.5% (59530/1,683,785) respectively; the inhospital morbidity rate was 35.8% (602,795/1,683,785). The incidence of in-hospital mortality and complications in COVID-19 patients without intracardiac thrombosis (Table 2).

#### Factors associated with intracardiac thrombosis

Table 3 shows the multivariable analysis results for factors associated with intracardiac thrombosis. Female patients had a lower risk of intracardiac thrombosis (OR: 0.46, 95%CI: 0.36-0.58, p<0.001). Amongst racial groups, Native Americans had the highest risk (OR: 4.93, 95%CI: 2.32-10.47, p<0.001), followed by African Americans (OR: 2.68, 95%CI: 2.06-3.50, p<0.001). The clinical comorbidities most strongly associated with intracardiac thrombosis include a history of congestive heart failure (OR: 7.44, 95%CI: 5.37-10.32, p<0.001) and coagulopathy (OR: 1.70, 95%CI: 1.23-2.37, p=0.001). Compared to asymptomatic COVID-19 infection, symptomatic patients had a lower risk (OR: 0.62, 95%CI: 0.50-0.77, p<0.001), while those with severe symptoms had a higher risk (OR: 2.11, 95%CI: 1.32-3.37, p<0.001) of intracardiac thrombosis.

# Predictors of in-hospital mortality

Figure 1 illustrates the univariable and multivariable odds ratios of intracardiac thrombosis and in-hospital outcomes. Full multivariable analyses of results for in-hospital deaths are presented in Table 4. Intracardiac thrombosis was independently associated with a higher risk of in-hospital all-cause mortality (multivariable OR: 3.32, 95%CI: 2.42-4.54, p<0.001) and cardiovascular-related mortality (OR: 2.95, 95%CI: 1.96-4.44, p<0.001). Female patients had a lower risk of all-cause mortality (OR: 0.74, 95%CI: 0.73-0.75, p<0.001) and cardiovascular mortality (OR: 0.67, 95%CI: 0.66-0.69, p<0.001). Among all the racial and ethnic groups studied, Native Americans were associated with the highest risk of in-hospital mortality (OR: 4.93, 95% CI 2.32-10.47, p<0.001). Compared to asymptomatic patients, symptomatic patients (OR: 3.22, 95%CI: 3.09-3.37, p<0.001 and OR: 2.90 95%CI: 2.71-3.10, p<0.001) and those with severe symptoms (OR: 2.79, 95%CI: 2.71-2.88, p<0.001 and OR: 2.20, 95%CI: 2.11-2.30, p<0.001) had higher risk of all-cause and cardiovascular-related mortality, respectively. The most important predictors of all-cause mortality were coagulopathy (OR: 2.55, 95%CI: 2.50-2.60, p<0.001), liver disease (OR: 2.52, 95%CI: 2.47-2.57, p<0.001), and cardiac arrhythmias (OR: 2.09, 95% CI: 2.05-2.14, p<0.001). For mortality due to cardiovascular causes, the most important predictors were cardiac arrhythmias (OR: 5.12, 95%CI: 4.98-5.26, p<0.001), congestive heart failure (OR: 3.24 95%CI: 3.14-3.34, p<0.001), and liver disease (OR: 2.71, 95%CI: 2.64-2.79, p<0.001).

#### In-hospital complications and predictors

Multivariable analyses for in-hospital complications are presented in Table 5. Intracardiac thrombosis was associated with a higher risk of cardiac arrest (OR: 2.04, 95%CI: 1.22-3.43, p=0.006), ACS (OR: 1.62, 95%CI: 1.17-2.22, p=0.003), stroke (OR: 3.10, 95%CI: 2.11-4.56, p<0.001), and AKI (OR: 2.13 95%CI: 1.68-2.69, p<0.001) but was statistically not associated

with heart failure (OR 1.32, 95% CI 0.80-2.17, p=0.27). Age per 10 years was associated with all in-hospital complications. Females had a lower risk of cardiac arrest, ACS, stroke and AKI but a higher risk of heart failure. The most important predictors for cardiac arrest were cardiac arrhythmia (OR: 4.89, 95%CI: 4.75-5.03, p<0.001) and liver disease (OR: 2.43, 95%CI: 2.36-2.59, p<0.001). For ACS, the most important predictors were congestive heart failure (OR: 2.83, 95%CI: 1.78-2.88, p<0.001) and cardiac arrhythmias (OR: 1.87 95%CI: 1.84-1.91, p<0.001). For heart failure, the most important predictors were pulmonary circulation disease (OR: 1.88, 95%CI: 1.82-1.94, p<0.001) and chronic pulmonary disease (OR: 1.68, 95%CI: 1.64-1.72, p<0.001). For stroke, the most important predictors were prior history of cerebrovascular accident (OR: 2.26, 95%CI: 2.21-2.30, p<0.001) and hypertension (OR: 2.22, 95%CI: 2.16-2.27, p<0.001). The most important predictors of AKI were renal failure (OR: 3.37, 95%CI: 3.32-3.42, p<0.001) and coagulopathy (OR: 1.69, 95%CI: 1.66-1.71, p<0.001).

# DISCUSSION

Our study studied the incidence of intracardiac thrombosis in patients with COVID-19 and its association with various comorbidities, end-organ damage, and patient mortality. The incidence of intracardiac thrombosis in patients with COVID-19 was found to be 0.001%. Key predictors of intracardiac thrombosis were identified. Intracardiac thrombosis was independently associated with a higher risk of in-hospital death (all-cause and cardiovascular) and most in-hospital complications (cardiac arrest, ACS, stroke, and AKI).

# Predictors of Intracardiac thrombosis in COVID-19

Apart from primarily infecting the respiratory tract, COVID-19 is widely recognized for its multisystemic involvement and a multitude of potentially devastating complications.<sup>10</sup> Nearly 36% of patients with COVID-19 have some cardiovascular involvement, which can include myocardial infarction, cardiomyopathy, arrhythmias, and myocarditis, and these patients are found to have worse clinical outcomes.<sup>10-12</sup> Dweck et al. found that 55% of the patients with COVID-19 have some abnormalities on echocardiography irrespective of comorbidities and symptoms.<sup>13</sup> Abnormally elevated troponin levels have been found in 27% to 71% of patients with COVID-19, with nearly 40% having worse outcomes.<sup>14,15</sup> Many previous studies have also shown that COVID-19 infection causes a hypercoagulable state that can lead to venous and arterial thromboembolism.<sup>16-18</sup>

Previously, many patients with COVID-19 have been documented to develop intracardiac thrombosis.<sup>4-8</sup> Intracardiac thrombosis is usually seen in patients with endocardial disease, prosthetic valves, intracardiac devices, contraction anomalies, or thrombophilia.<sup>19</sup> However, occurrence of intracardiac thrombosis has also been documented in normally contracting heart in patients with COVID-19.<sup>7,19</sup> Cases have been reported with biatrial thrombosis, biventricular thrombosis, and valvular thrombosis without any signs of infective endocarditis or coagulopathy.<sup>19-21</sup> These thrombotic complications have occurred despite the early pharmacological thromboprophylaxis administration in hospitalized COVID-19 patients. Previous observational studies have shown the incidence of intracardiac thrombosis in 17 out of 1,010 patients (0.017%) and 5 out of 630 patients (0.008%) with COVID-19.<sup>6,22,23</sup> Yuan et al performed echocardiography on all hospitalized patients with COVID-19 and found intracardiac thrombus in 2 out of 434 patients (0.0046%).<sup>24</sup>

Our large-scale nationwide study showed the incidence of intracardiac thrombosis in COVID-19 inpatients was 0.001%, which although rare may have important clinical consequences. The presence of multiple factors associated with intracardiac thrombosis, including male sex, non-Caucasian ethnicities especially Native Americans, heart failure, prior stroke and coagulopathy, should alert clinicians to a higher suspicion for intracardiac thrombosis if there are concerning clinical symptoms or deterioration in COVID-19 inpatients. Women having lower risk than men for intracardiac thrombosis is interesting, and this might be explained by the gender differences in the expression of ACE-2 receptors due to higher levels of androgens in men. These surface receptors line the endothelial cells and cells in other organ systems and are a site for viral entry.<sup>25</sup> Furthermore, gender differences in innate immunity may also be involved.<sup>26</sup>

#### Adverse outcomes of intracardiac thrombosis in COVID-19

In our study, intracardiac thrombosis was found to be associated with higher risk of all-cause and cardiovascular mortality, cardiac arrest, ACS, stroke, and AKI, highlighting the clinical significance of this finding. The common and most plausible mechanism is of course an embolic event to the coronary, carotid, and renal vessels respectively, resulting in a lifethreatening complication. Severely symptomatic COVID-19 was also associated with heart failure in our analyses, however given that history of heart failure is an established risk factor of intracardiac thrombosis (especially in the left ventricle), it is more likely that heart failure precedes intracardiac thrombosis. A recent study showed worse clinical outcomes in STelevation myocardial infarction (STEMI) patients with COVID-19 with higher overall thrombus burden and higher incidence of cardiac arrest, multivessel thrombosis, stent thrombosis, and in-hospital mortality compared to STEMI patients without COVID-19.<sup>27</sup> Interestingly, men had higher risk of all in-hospital complications except heart failure. Despite having higher risk of ACS, stroke, and AKI than some of the other races, our study found that Caucasian patient population had the lowest risk of mortality amongst all the races. African American patients had the highest risk for heart failure, stroke, and AKI, while patients belong to the group of "other" races had the highest risk of cardiac arrest and ACS. These disparities might be explained due to the genetic differences, differences in general health status, health-associated social factors, and inequity in access to healthcare services.<sup>28,29</sup>

# **Clinical implications**

Intracardiac thrombosis is more frequently found in left-sided cardiac chambers compared to the right side. Lee et al reported 130 events of intracardiac thrombosis after screening 86,374 patients with echocardiography out of which 47.4% were located in left ventricle (LV), 37.7% in left atrium (LA), 11.5% in the right atrium (RA) and 3.1% in the right ventricle (RV).<sup>30</sup> The main causes of LV thrombus include ST-elevation myocardial infarction (STEMI) (incidence: 2.9%-15%) and non-ischemic cardiomyopathies (incidence: 2-36%), while LA thrombus is most frequently seen in patients with atrial fibrillation (AF) (incidence: 5%-27% without anticoagulation), with 90% occurring in the left atrial appendage (LAA).<sup>31-</sup> <sup>34</sup> Deep venous thrombosis (DVT) is the most common cause of thrombosis in right cardiac chambers.<sup>35</sup> Abnormal elevation of certain lab values has been shown to predict a higher risk of intracardiac thrombosis in COVID-19 patients, including ALT, D-dimer, proBNP, and HS troponin T.<sup>23</sup>

Transthoracic echocardiography (TTE) is usually the first imaging technique for bedside assessment of intracardiac thrombus.<sup>36</sup> However, TTE can be difficult in patients with small intercostals spaces, large body habitus, lung diseases leading to poor acoustic windows. Transesophageal echocardiography (TEE) can be used in such patients due to its better visualization of the left atrium (which is directly adjacent to the esophagus) and thus higher sensitivity for detecting LAA thrombus.<sup>37</sup> This can be supplemented by the use of echocardiographic contrast (ECA) and harmonic imaging to further improve the sensitivity and specificity. Studies have shown that the use of ECA can improve the sensitivity from 33% to 100% and specificity from 82% to 92% in LVT detection.<sup>38,39</sup> Cardiac MR with gadolinium contrast is another imaging technique that can be used for detection of intracardiac thrombus along with other structural cardiac anomalies. A study showed that cardiac MR had the highest sensitivity (88%) and specificity (99%) compared to TEE (40% and 96%) and TTE (23% and 96%) for detection of LVT.<sup>37,40</sup> However, the high cost and less availability limits the broad use of cardiac MR. Contrast-enhanced CT is another technique that can be used with 65 Hounsfield units as a threshold for intracardiac thrombus.<sup>41</sup> The limitations include radiation exposure and use of intravenous contrast.

It is also important to ensure appropriate transmission prevention in COVID-19 patients while performing these studies. European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE) guidelines do not recommend echocardiography being routinely performed in patients with COVID-19.<sup>42,43</sup> Screening should be clinically driven based on symptoms. Anticoagulation is the mainstay of treatment. Vitamin-K antagonists (VKAs) have been conventionally used for a period 3-6 months.<sup>44</sup> Recently, direct oral anticoagulants (DOACs) have also been used to treat intracardiac thrombus. Despite the lack of randomized controlled trials (RCTs) data, DOACs have several advantages over VKAs:

rapid onset of action, short half-lives permitting fixed dose regimens, oral route of administration, and lack of requirement of lab monitoring.<sup>45</sup> Recent studies have shown thrombus resolution rates ranging from 83% to 90% with lower risks of bleeding and variable risk of embolization.<sup>45-47</sup> The American Heart Association recommends the use of low molecular heparin, dabigatran, apixaban, and rivaroxaban in cases of warfarin intolerance.<sup>44</sup> The duration of therapy depends on the etiology and risk of thrombosis. Patients with reversible causes such as infection, resolved cardiomyopathy, or atrial fibrillation with low CHA<sub>2</sub>DS<sub>2</sub>-VASC scores require shorter duration compared to those with persistent risk factors. In hemodynamically unstable patients, surgical thrombectomy may be used on a case-to-case basis.<sup>44</sup>

### Limitations

Our study has some limitations. This is a retrospective observational study with intrinsic biases but represents amongst the largest COVID-19 experience to date evaluating intracardiac thrombosis as part of the NIS database. The true prevalence of intracardiac thrombosis is likely higher than reported, as most patients would not have undergone all the tests for detecting thrombosis, and the method of evaluation may differ in utility and accuracy in different healthcare practices. The type of intracardiac thrombosis, whether left atrial appendage, left or right atrial or ventricular cannot be distinguished via the diagnostic coding of the NIH database for subgroup analyses. The time course of the development of intracardiac thrombosis to the COVID-19 infection is unknown, and may have been causally related, incidental, or even pre-existing. Studies have shown that intracardiac thrombus may be found from 5 to 25 days and up to 80 days in cases of delayed thrombosis.<sup>48,49</sup> Patients may develop intracardiac thrombosis after being treated for acute COVID-19 illness and discharged from the hospital. Our study lacks data on those patients since NIS does not track

patients' post-discharge. Lastly, we lack the data on laboratory tests results, imaging modalities and treatments used in the NIS dataset to allow for analyses.

# Conclusion

In conclusion, incidence of intracardiac thrombosis was 0.001% in COVID-19 in this large representative US inpatient sample. Intracardiac thrombosis was associated with a higher risk of mortality (all-cause and cardiovascular) and some in-hospital complications (cardiac arrest, ACS, stroke, and AKI). Key factors associated with intracardiac thrombosis include male sex, non-Caucasian ethnicities especially Native Americas, heart failure, prior stroke and coagulopathy, and the presence of several of these factors should alert clinicians to a higher suspicion for intracardiac thrombosis if there are concerning clinical symptoms or deterioration in COVID-19 inpatients.

# References

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395:497-506. doi: 10.1016/s0140-6736(20)30183-5
- Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. 2020;46:1603-1606. doi: 10.1007/s00134-020-06088-1
- Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K.
   Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging

evidence and call for action. *British journal of haematology*. 2020;189:846-847. doi: 10.1111/bjh.16727

- Arslan U, Borulu F. Chronic intracardiac thrombus, a long-term complication of COVID-19: Case reports. 2021;36:3939-3943. doi: 10.1111/jocs.15836
- Karikalan S, Sharma M, Chandna M, Sachdev M, Gaalla A, Yasmin F, Shah R, Ratnani I, Surani S. Intracardiac Thrombus in Coronavirus Disease-2019. *Cureus*. 2022;14:e22883. doi: 10.7759/cureus.22883
- Berrichi S, Bouayed Z, Benbouchta K, Kossir A, Bkiyar H, Ismaili N, Ouafi NE, Housni B. Incidental diagnosis of a large cardiac thrombus swinging through an interatrial communication in a COVID-19 patient: Case report and literature review. *Annals of medicine and surgery (2012)*. 2021;71:102967. doi: 10.1016/j.amsu.2021.102967
- Calvi E, Bernardi N, Cimino G. Unusual intracardiac thrombosis in two patients with coronavirus disease 2019 (COVID-19): case series. 2021;5:ytaa518. doi: 10.1093/ehjcr/ytaa518
- Iqbal M, Sethi SM, Hanif S. Extra-Pulmonary Thrombosis In Patients With Coronavirus-19 Disease; Case Series And Review Of The Literature. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2022;34:557-562. doi: 10.55519/jamc-03-10382
- (AHRQ) HCaUPHuAfHRaQ. The National (Nationwide) Inpatient Sample (NIS) https://hcup-us.ahrq.gov/nisoverview.jsp. 2020.
- Roberts CM, Levi M, McKee M, Schilling R, Lim WS, Grocott MPW. COVID-19: a complex multisystem disorder. *British journal of anaesthesia*. 2020;125:238-242. doi: 10.1016/j.bja.2020.06.013

- 11. Zheng YY, Ma YT. COVID-19 and the cardiovascular system. 2020;17:259-260. doi: 10.1038/s41569-020-0360-5
- Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *Journal of the American College of Cardiology*. 2020;75:2352-2371. doi: 10.1016/j.jacc.2020.03.031
- Dweck MR, Bularga A, Hahn RT, Bing R, Lee KK, Chapman AR, White A, Salvo GD, Sade LE, Pearce K, et al. Global evaluation of echocardiography in patients with COVID-19. *European heart journal Cardiovascular Imaging*. 2020;21:949-958. doi: 10.1093/ehjci/jeaa178
- Knight DS, Kotecha T, Razvi Y, Chacko L, Brown JT, Jeetley PS, Goldring J, Jacobs M, Lamb LE, Negus R, et al. COVID-19: Myocardial Injury in Survivors.
   *Circulation*. 2020;142:1120-1122. doi: 10.1161/circulationaha.120.049252
- Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A metaanalysis. *The American journal of emergency medicine*. 2021;44:352-357. doi: 10.1016/j.ajem.2020.04.052
- Burn E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, Kostka K, Delmestri A, Rijnbeek P, Verhamme K, Prieto-Alhambra D. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. *The Lancet Infectious diseases*. 2022;22:1142-1152. doi: 10.1016/s1473-3099(22)00223-7
- Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B.Thromboembolism risk of COVID-19 is high and associated with a higher risk of

mortality: A systematic review and meta-analysis. *EClinicalMedicine*. 2020;29:100639. doi: 10.1016/j.eclinm.2020.100639

- Tan BK, Mainbourg S, Friggeri A, Bertoletti L. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. 2021;76:970-979. doi: 10.1136/thoraxjnl-2020-215383
- Elikowski W, Fertała N, Zawodna-Marszałek M, Skrzywanek P, Łazowski S, Kurzawa A, Szczęśniewski P, Gaca-Wysocka M, Sokołowski K, Żytkiewicz M. Native heart valve thrombosis associated with COVID-19 - a report of 4 cases. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2022;50:312-317.
- 20. Ghodsi S, Taghi S, Alizadeh-Sani Z, Jenab Y, Hosseini Z, Vaskelyte L. Association of COVID-19 infection with large thrombi in left and right atrial appendages. *The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology*. 2021;73:81. doi: 10.1186/s43044-021-00207-z
- Torres R, Gul F, Azmaiparashvili Z. Bi-atrial thrombosis in a patient with SARS-CoV-2 infection: a case report. 2020;4:1-5. doi: 10.1093/ehjcr/ytaa367
- El Aidouni G, Merbouh M, Aabdi M, Bouabdallaoui A, Bkiyar H, Smaili N, Elouafi N, Housni B. Intra cardiac thrombus in critically ill patient with coronavirus disease 2019: Case report. *Annals of medicine and surgery (2012)*. 2021;66:102434. doi: 10.1016/j.amsu.2021.102434
- 23. Rastogi S, Azari B, Henry S. PREDICTORS OF COVID-19 RELATED INTRA-CARDIAC THROMBUS FROM ADMISSION LABORATORY VALUES. *Journal of the American College of Cardiology*. 2021;77:3182-3182. doi: doi:10.1016/S0735-1097(21)04537-X
- Yuan N, Wu S, Rader F, Siegel RJ. Determining Which Hospitalized CoronavirusDisease 2019 Patients Require Urgent Echocardiography. *Journal of the American*

Society of Echocardiography : official publication of the American Society of Echocardiography. 2021;34:831-838. doi: 10.1016/j.echo.2021.03.010

- Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Jänne OA. Androgen receptor and androgen-dependent gene expression in lung. *Molecular and cellular endocrinology*. 2010;317:14-24. doi: 10.1016/j.mce.2009.12.022
- Klein SL, Flanagan KL. Sex differences in immune responses. *Nature reviews Immunology*. 2016;16:626-638. doi: 10.1038/nri.2016.90
- 27. Rathod KS, Teoh Z, Tyrlis A, Choudry FA, Hamshere SM, Comer K, Guttmann O, Jain AK, Ozkor MA, Wragg A, et al. Thrombus Burden and Outcomes in Patients With COVID-19 Presenting With STEMI Across the Pandemic. *Journal of the American College of Cardiology*. 2023;81:2406-2416. doi: 10.1016/j.jacc.2023.04.029
- Friedman DJ, Pollak MR. APOL1 and Kidney Disease: From Genetics to Biology. *Annual review of physiology*. 2020;82:323-342. doi: 10.1146/annurev-physiol-021119-034345
- 29. Chang MH, Moonesinghe R, Truman BI. COVID-19 Hospitalization by Race and Ethnicity: Association with Chronic Conditions Among Medicare Beneficiaries, January 1-September 30, 2020. *Journal of racial and ethnic health disparities*.
  2022;9:325-334. doi: 10.1007/s40615-020-00960-y
- 30. Lee JM, Park JJ, Jung HW, Cho YS, Oh IY, Yoon CH, Suh JW, Chun EJ, Choi SI, Youn TJ, et al. Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. *Journal of atherosclerosis and thrombosis*. 2013;20:73-93. doi: 10.5551/jat.13540
- Zhan Y, Joza J, Al Rawahi M, Barbosa RS, Samuel M, Bernier M, Huynh T, Thanassoulis G, Essebag V. Assessment and Management of the Left Atrial

Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation. *The Canadian journal of cardiology*. 2018;34:252-261. doi: 10.1016/j.cjca.2017.12.008

- 32. Wyrembak J, Campbell KB, Steinberg BA, Bahnson TD, Daubert JP, Velazquez EJ, Samad Z, Atwater BD. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. *The American journal of cardiology*. 2017;119:1017-1022. doi: 10.1016/j.amjcard.2016.12.008
- Cruz Rodriguez JB, Okajima K, Greenberg BH. Management of left ventricular thrombus: a narrative review. *Annals of translational medicine*. 2021;9:520. doi: 10.21037/atm-20-7839
- Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. *Heart (British Cardiac Society)*. 1999;82:547-554. doi: 10.1136/hrt.82.5.547
- Lai E, Alishetti S, Wong JM, Delic L, Egrie G, Rosenblatt A. Right Ventricular
   Thrombus in Transit: Raising the Stakes in the Management of Pulmonary Embolism.
   *CASE (Philadelphia, Pa)*. 2019;3:272-276. doi: 10.1016/j.case.2019.05.006
- 36. Visser CA, Kan G, David GK, Lie KI, Durrer D. Two dimensional echocardiography in the diagnosis of left ventricular thrombus. A prospective study of 67 patients with anatomic validation. *Chest.* 1983;83:228-232. doi: 10.1378/chest.83.2.228
- Patel M, Wei X, Weigel K, Gertz ZM, Kron J, Robinson AA, Trankle CR. Diagnosis and Treatment of Intracardiac Thrombus. 2021;78:361-371. doi: 10.1097/fjc.000000000001064
- 38. Weinsaft JW, Kim RJ, Ross M, Krauser D, Manoushagian S, LaBounty TM, Cham MD, Min JK, Healy K, Wang Y, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular

thrombus. *JACC Cardiovascular imaging*. 2009;2:969-979. doi: 10.1016/i.icmg.2009.03.017

- Wada H, Yasu T, Sakakura K, Hayakawa Y, Ishida T, Kobayashi N, Kubo N, Ako J,
   Momomura S. Contrast echocardiography for the diagnosis of left ventricular
   thrombus in anterior myocardial infarction. *Heart and vessels*. 2014;29:308-312. doi: 10.1007/s00380-013-0363-9
- 40. Delewi R, Nijveldt R, Hirsch A, Marcu CB, Robbers L, Hassell ME, de Bruin RH, Vleugels J, van der Laan AM, Bouma BJ, et al. Left ventricular thrombus formation after acute myocardial infarction as assessed by cardiovascular magnetic resonance imaging. *European journal of radiology*. 2012;81:3900-3904. doi: 10.1016/j.ejrad.2012.06.029
- Bittencourt MS, Achenbach S, Marwan M, Seltmann M, Muschiol G, Ropers D, Daniel WG, Pflederer T. Left ventricular thrombus attenuation characterization in cardiac computed tomography angiography. *Journal of cardiovascular computed tomography*. 2012;6:121-126. doi: 10.1016/j.jcct.2011.12.006
- 42. Echocardiography ASo. ASE Statement on COVID-19. https://www.asecho.org/asestatement-covid-19/. 2020.
- ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.
   *Cardiovascular research*. 2022;118:1618-1666. doi: 10.1093/cvr/cvab343
- Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood advances*. 2020;4:4693-4738. doi: 10.1182/bloodadvances.2020001830

- 45. Ghaffarpasand E, Tehrani MD, Marszalek J, Chi G. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. 2018;46:332-338. doi: 10.1007/s11239-018-1693-3
- Lattuca B, Bouziri N, Kerneis M, Portal JJ, Zhou J, Hauguel-Moreau M, Mameri A, Zeitouni M, Guedeney P, Hammoudi N, et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. *Journal of the American College of Cardiology*. 2020;75:1676-1685. doi: 10.1016/j.jacc.2020.01.057
- 47. Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, Gottiparthi S, Ruth B, Kramer CM, Salerno M, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. *JAMA cardiology*. 2020;5:685-692. doi: 10.1001/jamacardio.2020.0652
- 48. Fan BE, Umapathi T, Chua K, Chia YW, Wong SW, Tan GWL, Chandrasekar S, Lum YH, Vasoo S, Dalan R. Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. *Journal of thrombosis and thrombolysis*. 2021;51:971-977. doi: 10.1007/s11239-020-02332-z
- 49. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *The New England journal of medicine*. 2020;382:e38. doi: 10.1056/NEJMc2007575

# Table 1: Baseline characteristics of COVID-19 patients with and without intracardiac

thrombosis

Variables	COVID-19 with	COVID-19 without	Devalue
Variables	intracardiac thrombosis	intracardiac thrombosis	P-value
Total patients	1,830	1,682,045	
Age (years)	63.8±1.6	63.5±0.2	0.45
Female	590 (32.2%)	806,855 (48%)	<0.001
Median length of stay(IQR))	8 (4-14)	5 (3-10)	
Race		I	<0.001
Caucasian	780 (42.5%)	853,518 (50.7%)	
African American	580 (31.5%)	319,840 (19%)	
Hispanic	270 (14.6%)	364,490 (21.7%)	
Asian or Pacific Islander	85 (4.5%)	54,465 (3.2%)	
Native American	25 (1.2%)	17,255 (1%)	
Other	90 (4.7%)	72,463 (4.3%)	
Region			<0.001
Northeast	300 (16.4%)	309,260 (18.4%)	
Midwest	465 (25.4%)	374,300 (22.3%)	
South	675 (36.9%)	691,405 (41.1%)	
West	390 (21.3%)	307,080 (18.2%)	
Hospital type			<0.001
Urban (Non-teaching)	220 (12%)	316,956 (18.5%)	
Urban (Teaching)	1,545 (84.4%)	1,207,884 (71.8%)	
Rural	65 (3.6%)	163,245 (9.7%)	

Hospital size			<0.001
Small	285 (15.5%)	407,930 (24.3%)	
Medium	485 (26.5%)	486,840 (28.9%)	
Large	1,060 (58%)	787,275 (46.8%)	
Presentation			
Asymptomatic	631 (34.5%)	403,691 (24.8%)	<0.001
Symptomatic	1,191 (65.1%)	1,244,713 (74.9%)	<0.001
Severe	993 (54.3%)	925,125 (55.6%)	<0.001
Comorbidities			
Hypertension	1,395 (76.2%)	1,079,265 (64.2%)	<0.001
Diabetes mellitus	715 (39%)	665,380 (39.5%)	<0.001
Hyperlipidemia	802 (43.7%)	612,115 (36.4%)	<0.001
Atrial fibrillation	675 (36.9%)	265,560 (15.8%)	<0.001
Stroke	335 (18.3%)	143,260 (8.5%)	<0.001
Obesity	346 (18.9%)	435,650 (25.9%)	<0.001
Smoking	617 (33.7%)	444,060 (26.4%)	<0.001
Alcohol abuse	55 (3.0%)	45,415 (2.7%)	0.20
Pulmonary circulation disorders	346 (18.9%)	89,148 (5.3%)	<0.001
Peripheral vascular disorder	340 (18.6%)	80,738 (4.8%)	<0.001
Cardiac arrhythmias	917 (50.1%)	418,830 (24.9%)	<0.001
Congestive heart failure	1,263 (69.0%)	297,722 (17.7%)	<0.001
Chronic pulmonary disease	372 (20.3%)	373,414 (22.2%)	<0.001
Renal failure	620 (33.9%)	358,275 (21.3%)	<0.001

Liver disease	183 (10.0%)	92,512 (5.5%)	<0.001
AIDS/HIV	9 (0.5%)	3,365 (0.2%)	0.41
Rheumatoid arthritis/Collagen vascular disease	40 (2.2%)	48,780 (2.9%)	0.11
Blood loss anemia	20 (1.10%)	6,728 (0.4%)	0.08
Deficiency anemia	92 (5.0%)	65,600 (3.9%)	<0.001
Solid tumor without metastasis	75 (4.1%)	40,370 (2.4%)	<0.001
Metastatic cancer	46 (2.5%)	18,502 (1.1%)	<0.001
Lymphoma	9 (0.5%)	11,774 (0.7%)	0.05

Abbreviation: IQR: Interquartile range

Outcomes	Overall cohort	COVID-19 without	COVID-19 with	p-value
Outcomes	Overall conort	intracardiac thrombosis	intracardiac thrombosis	
In-hospital mortality	13.2% (222,695/1,683,785)	13.2% (222,385/1,682,045)	16.9% (310/1,830)	0.007
Cardiovascular mortality	3.5% (59,530/1,683,785)	3.5% (59,370/1,682,045)	8.7% (160/1,830)	0.001
Cardiac arrest	2.6% (44,145/1,683,785)	2.6% (44,055/1,682,045)	4.9% (90/1,830)	0.003
Acute coronary syndrome	4.4% (74,940/1,683,785)	4.4% (74670/1,682,045)	14.8% (270/1,830)	<0.001
Heart failure	16.1% (272,140/1,683,785)	16.1% (270,955/1,682,045)	64.8% (1,185/1,830)	<0.001
Stroke	1.3% (22,030/1,683,785)	1.2% (21845/1,682,045)	10.1% (185/1,830)	<0.001
Acute kidney injury	28.3% (476,820/1,683,785)	28.2% (475,955/1,682,045)	47.3% (865/1,830)	<0.001

Table 2: Incidence of outcomes in overall COVID-19 cohort, COVID-19 with and without intracardiac thrombosis

Predictors	OR (95%CI)	P-value		
Demographic				
Age (per 10 years)	0.99 (0.99-1.00)	0.35		
Female	0.46 (0.36-0.58)	<0.001		
Race				
Caucasian	Reference			
African American	2.68 (2.06-3.50)	<0.001		
Hispanic	2.28 (1.65-3.14)	<0.001		
Asian or Pacific Islander	2.54 (1.51-4.28)	<0.001		
Native American	4.93 (2.32-10.47)	<0.001		
Other	2.54 (1.51-4.28)	<0.001		
Region				
Northeast	Reference			
Midwest	1.53 (1.06-2.22)	0.02		
South	1.06 (0.74-1.52)	0.75		
West	1.10 (0.75-1.64)	0.61		
Hospital location				
Rural	Reference			
Urban non-teaching	1.33 (0.72-2.45)	0.35		
Urban teaching	2.13 (1.24-3.65)	0.006		
Hospital size				
Small	Reference			

# Table 3: Predictors of intracardiac thrombosis in COVID-19 patients

Medium	1.32 (0.94-1.85)	0.11
Large	1.57 (1.54-2.14)	0.004
Presentation		
Asymptomatic	Reference	
Symptomatic	0.62 (0.50-0.77)	<0.001
Severely symptomatic	2.11 (1.32-3.37)	0.002
Comorbidities		
Hypertension	0.92 (0.67-1.27)	0.63
Diabetes mellitus	0.85 (0.67-1.07)	0.17
Hyperlipidemia	1.05 (0.83-1.33)	0.68
Obesity	0.81 (0.61-1.08)	0.14
Alcohol abuse	0.34 (0.18-0.65)	0.001
Smoking	0.81 (0.64-1.03)	0.08
Congestive heart failure	7.66 (5.37-10.9)	<0.001
Cardiac arrhythmias	1.58 (1.12-2.23)	0.01
Atrial fibrillation	0.96 (0.68-1.34)	0.80
Valvular disease	0.48 (0.33-0.70)	<0.001
Peripheral Vascular disease	1.35 (0.99-1.83)	0.05
Pulmonary circulation disease	1.93 (1.39-2.69)	<0.001
Chronic pulmonary disease	0.58 (0.44-0.76)	<0.001
Prior cerebrovascular accident	1.59 (1.12-2.12)	0.001
Renal failure	0.74 (0.57-0.96)	0.02
Liver disease	1.24 (0.85-1.81)	0.26

Coagulopathy	1.67 (1.20-2.32)	0.002
Thrombophilia	1.33 (1.20-1.47)	<0.001
AIDS/HIV	1.01 (0.25-4.08)	0.99
Rheumatoid arthritis	0.47 (0.21-1.05)	0.06
Blood loss anemia	1.17 (0.43-3.16)	0.75
Deficiency anemia	0.76 (0.48-1.22)	0.26
Solid tumor without metastasis	0.72 (0.37-1.39)	0.32
Metastatic cancer	0.82 (0.35-1.93)	0.65
Lymphoma	0.37 (0.09-1.49)	0.16

Abbreviations: OR: odds ratio; 95%CI: confidence interval

# Table 4: Predictors of in-hospital mortality (all-cause and cardiovascular) in COVID-19

patients

Predictors	All-cause mo	rtality	Cardiovascular mortality		
	OR (95% CI)	P-value	OR (95% CI)	P-value	
Intracardiac thrombus	3.32 (2.42-4.54)	< 0.001	2.95 (1.96-4.44)	<0.001	
Demographics					
Age (per 10 years)	1.48 (1.34-1.50)	< 0.001	1.21 (1.10-1.22)	<0.001	
Female gender	0.74 (0.73-0.75)	< 0.001	0.67 (0.66-0.69)	<0.001	
Race					
Caucasian	Reference		Reference		
African American	1.22 (1.19-1.26)	<0.001	1.35 (1.31-1.40)	<0.001	
Hispanic	1.26 (1.231.30)	< 0.001	1.32 (1.26-1.38)	<0.001	
Asian or Pacific Islander	1.20 (1.15-1.25)	<0.001	1.19 (1.12-1.26)	<0.001	
Native American	1.58 (1.44-1.75)	< 0.001	1.41 (1.26-1.57)	<0.001	
Other	1.34 (1.27-1.40)	< 0.001	1.39 (1.31-1.48)	<0.001	
Region					
Northeast	Reference		Reference		
Midwest	0.93 (0.88-0.98)	0.006	1.06 (0.99-1.12)	0.05	
South	0.96 (0.92-1.01)	0.140	1.19 (1.12-1.25)	<0.001	
West	0.92 (0.88-0.97)	0.003	1.08 (1.01-1.14)	0.01	
Hospital size					
Small	Reference		Reference		

Medium	1.17 (1.12-1.22)	< 0.001	1.16 (1.11-1.22)	<0.001
Large	1.25 (1.20-1.31)	< 0.001	1.17 (1.11-1.22)	<0.001
Hospital location				
Rural	Reference		Reference	
Urban non-teaching	1.07 (1.01-1.12)	0.014	1.24 (1.16-1.32)	<0.001
Urban teaching	1.23 (1.17-1.29)	< 0.001	1.36 (1.28-1.44)	<0.001
Presentation				
Asymptomatic	Reference		Reference	
Symptomatic	3.22 (3.09-3.37)	< 0.001	2.90 (2.71-3.10)	<0.001
Severely symptomatic	2.79 (2.71-2.88)	< 0.001	2.20 (2.11-2.30)	<0.001
Comorbidities	<u> </u>		<u> </u>	
Hypertension	0.70 (0.68-0.71)	< 0.001	0.79 (0.77-0.81)	<0.001
Diabetes mellitus	1.10 (1.09-1.12)	< 0.001	1.17 (1.15-1.20)	<0.001
Hyperlipidemia	0.69 (0.67-0.70)	< 0.001	0.70 (0.69-0.72)	<0.001
Obesity	0.91 (0.89-0.93)	< 0.001	0.85 (0.83-0.88)	<0.001
Alcohol abuse	0.71 (0.69-0.72)	< 0.001	0.63 (0.60-0.65)	<0.001
Smoking	0.60 (0.59-0.61)	< 0.001	0.63 (0.61-0.64)	<0.001
Congestive heart failure	1.38 (1.35-1.40)	< 0.001	3.24 (3.14-3.34)	<0.001
Cardiac arrhythmias	2.09-2.05-2.14)	< 0.001	5.12 (4.98-5.26)	<0.001
Atrial fibrillation	0.71 (0.69-0.72)	< 0.001	0.43 (0.41-0.44)	<0.001
Valvular disease	0.70 (0.69-0.71)	< 0.001	0.80 (0.78-0.82)	<0.001
Peripheral Vascular disease	1.03 (1.01-1.05)	0.008	1.14 (1.10-1.17)	<0.001

Pulmonary circulation	1 22 (1 20 1 25)	<0.001	1.25 (1.21, 1.28)	<0.001
disease	1.33 (1.30-1.35)	<0.001	1.25 (1.21-1.28)	<0.001
Chronic pulmonary disease	1.13 (1.12-1.15)	<0.001	1.04 (1.01-1.06)	0.001
Prior cerebrovascular accident	0.90 (0.88-0.91)	<0.001	0.82 (0.80-0.85)	<0.001
Renal failure	1.14 (1.12-1.15)	<0.001	1.17 (1.14-1.19)	<0.001
Liver disease	2.52 (2.47 (2.57)	<0.001	2.71 (2.64-2.79)	<0.001
Coagulopathy	2.55 (2.50-2.60)	<0.001	2.24 (2.18-2.30)	<0.001
Thrombophilia	0.97 (0.95-0.99)	0.025	0.96 (0.94-0.98)	<0.001
AIDS/HIV	1.41 (1.30-1.53)	< 0.001	1.19 (1.05-1.35)	0.007
Rheumatoid arthritis	0.92 (0.89-0.95)	< 0.001	0.85 (0.81-0.90)	<0.001
Blood loss anemia	0.68 (0.64-0.72)	< 0.001	0.74 (0.67-0.81)	<0.001
Deficiency anemia	0.67 (0.65-0.69)	< 0.001	0.63 (0.60-0.65)	<0.001
Solid tumor without metastasis	1.21 (1.18-1.24)	<0.001	1.03 (0.99-107)	0.19
Metastatic cancer	2.01 (1.95-2.06)	<0.001	1.42 (1.35-1.49)	<0.001
Lymphoma	1.16 (1.12-1.21)	<0.001	1.02 (0.95-10.09)	0.65

Abbreviations: OR: odds ratio; 95%CI: confidence interval

**Table 5:** Predictors of in-hospital complications in COVID-19 patients

Predictors	Cardiac arrest		Acute coronary syndrome		Heart failure		Stroke		Acute kidney injury	
	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р
Intracardiac thrombus	2.04 (1.22-3.43)	0.006	1.62 (1.17-2.22)	0.003	1.32 (0.80-2.17)	0.27	3.10 (2.11-4.56)	<0.001	2.13 (1.68-2.69)	<0.001
Demographics										
Female gender	0.70 (0.68-0.71)	<0.001	0.66 (0.66-0.67)	<0.001	1.32 (1.29-1.34)	<0.001	0.89 (0.88-0.90)	<0.001	0.70 (0.69-0.70)	<0.001
Age (per 10 years)	1.10 (1.10-1.21)	<0.001	1.10 (1.10-1.21)	<0.001	1.21 (1.10-1.22)	<0.001	1.21 (1.10-1.22)	<0.001	1.21 (1.10-1.22)	<0.001
Race										<u> </u>
Caucasian	Reference		Reference		Reference		Reference		Reference	
African American	1.51 (1.46-1.57)	<0.001	0.82 (0.80-0.85)	<0.001	1.38 (1.33-1.44)	<0.001	1.23 (1.20-1.26)	<0.001	1.25 (1.23-1.26)	<0.001
Hispanic	1.31 (1.25-1.38)	<0.001	0.92 (0.87-0.97)	0.001	1.18 (1.12-1.25)	<0.001	0.86 (0.83-0.89)	<0.001	0.88 (0.87-0.90)	<0.001
Asian or Pacific	1.28 (1.20-1.37)	<0.001	1.08 (1.03-1.13)	0.001	0.98 (0.90-1.07)	0.72	1.13 (1.08-1.19)	<0.001	0.88 (0.86-0.90)	<0.001

Islander										
Native American	1.25 (1.11-1.41)	<0.001	1.08 (0.97-1.20)	0.17	1.12 (0.99-1.25)	0.05	0.91 (0.82-1.01)	0.079	0.97 (0.92-1.02)	0.34
Other	1.54 (1.45-1.65)	<0.001	1.13 (1.06-1.20)	<0.001	1.16 (1.08-1.25)	<0.001	1.06 (1.01-1.12)	0.018	1.02 (1.01-1.06)	0.03
Region										
Northeast	Reference		Reference		Reference		Reference		Reference	
Midwest	1.14 (1.07-1.22)	<0.001	1.01 (0.94-1.10)	0.73	0.99 (0.93-1.07	0.95	1.09 (1.04-1.16)	0.001	0.99 (0.96-1.03)	0.65
South	1.33 (1.25-1.42)	<0.001	1.06 (0.99-1.15)	0.10	1.08 (1.02-1.15)	0.006	1.17 (1.11-1.24)	<0.001	1.07 (1.04-1.11)	<0.001
West	1.17 (1.09-1.26)	<0.001	1.08 (1.01-1.17)	0.04	1.24 (1.6-1.32)	<0.001	1.17 (1.10 (1.23)	<0.001	1.06 (1.03-1.10)	0.001
Hospital location										
Rural	Reference		Reference		Reference		Reference		Reference	
Urban non-teaching	1.28 (1.19-1.38)	<0.001	1.06 (0.98-1.14)	0.15	0.72 (0.67-0.78)	<0.001	1.15 (1.09-1.22)	<0.001	1.13 (1.09-1.16)	<0.001
Urban teaching	1.30 (1.21-1.39)	<0.001	0.14 (1.06-1.22)	0.001	0.78 (0.73-0.84)	<0.001	1.44 (1.37-1.52)	<0.001	1.17 (1.14-1.21)	<0.001
Hospital size										
Small	Reference		Reference		Reference		Reference		Reference	

Medium	1.13 (1.07-1.19)	<0.001	1.12 (1.05-1.19)	0.001	0.94 (0.89-0.99)	0.03	1.18 (1.13-1.23)	<0.001	1.02 (0.99-1.05)	0.10
Large	1.03 (0.98-1.08)	0.31	1.13 (1.06-1.20)	<0.001	0.95 (0.90-1.01)	0.08	1.40 (1.34-1.46)	<0.001	1.02 (0.99-1.05)	0.09
Presentation				<u> </u>	I					
Asymptomatic	Reference		Reference		Reference		Reference		Reference	
Symptomatic	2.57 (2.39-2.76)	<0.001	1.27 (1.21-1.33)	<0.001	0.97 (0.95-0.99)	0.02	0.58 (0.54-0.62)	<0.001	1.40 (1.37-1.43)	<0.001
Severely symptomatic	1.86 (1.76-1.95)	<0.001	1.48 (1.43-1.54)	<0.001	1.28 (1.25-1.30)	<0.001	0.59 (0.56-0.62)	<0.001	4.06 (3.98-4.15)	<0.001
Comorbidities										
Hypertension	0.87 (0.85-0.90)	<0.001	1.46 (1.44-1.49)	<0.001	1.45 (1.41-1.50)	<0.001	2.22 (2.16-2.27)	<0.001	1.21 (1.20-1.23)	<0.001
Diabetes mellitus	1.22 (1.19-1.24)	<0.001	1.04 (1.03-1.05)	<0.001	1.23 (1.20-1.26)	<0.001	1.11 (1.10-1.13)	<0.001	1.39 (1.38-1.40)	<0.001
Hyperlipidemia	0.76 (0.75-0.78)	<0.001	1.64 (1.61-1.67)	<0.001	0.78 (0.76-0.79)	<0.001	1.45 (1.43-1.48)	<0.001	0.89 (0.88-0.90)	<0.001
Obesity	1.00 (0.99-1.02)	0.80	1.02 (1.01-1.04)	0.009	1.48 (1.45-1.52)	<0.001	0.89 (0.87-0.90)	<0.001	1.18 (1.17-1.19)	<0.001
Alcohol abuse	0.75 (0.72-0.78)	<0.001	0.62 (0.61-0.64)	<0.001	0.91 (0.88-0.95)	<0.001	0.89 (0.87-0.92)	<0.001	0.99 (98-1.01)	0.77
Smoking	0.69 (0.67-0.71)	<0.001	1.17 (1.15-1.19)	<0.001	1.04 (1.02-1.06)	0.001	1.00 (0.99-1.02)	0.68	0.85 (0.84-0.85)	<0.001
Congestive heart	1.60 (1.55-1.64)	<0.001	2.83 (1.78-2.88)	<0.001	N/A		0.70 (0.69-0.71)	<0.001	1.28 (1.27-1.29)	<0.001

failure										
Cardiac arrhythmias	4.89 (4.75-5.03)	<0.001	1.87 (1.84-1.91)	<0.001	0.87 (0.84-0.89)	<0.001	1.05 (1.02-1.07)	<0.001	1.23 (1.22-1.25)	<0.001
Atrial fibrillation	0.42 (0.41-0.43)	<0.001	0.46 (0.46-0.47)	<0.001	1.57 (1.53-1.62)	<0.001	1.08 (1.06-1.11)	<0.001	0.84 (0.83-0.85)	<0.001
Valvular disease	0.77 (0.75-0.80)	<0.001	1.31 (1.29-1.34)	<0.001	1.44 (1.40-1.48)	<0.001	1.13 (1.11-1.16)	<0.001	0.88 (0.87-0.89)	<0.001
Peripheral Vascular disease	0.97 (0.94-1.00)	0.06	0.94 (0.92-0.96)	<0.001	1.00 (0.98-1.03)	0.842	0.97 (0.95-0.99)	0.01	0.97 (0.96-0.98)	<0.001
Pulmonary circulation disease	1.43 (1.38-1.48)	<0.001	1.07 (1.04-1.09)	<0.001	1.88 (1.82-1.94)	<0.001	0.82 (0.80-0.85)	<0.001	1.13 (1.12-1.14)	<0.001
Chronic pulmonary disease	1.02 (1.00-1.05)	0.05	0.77 (0.76-0.79)	<0.001	1.68 (1.64-1.72)	<0.001	0.58 (0.57-0.59)	<0.001	0.92 (0.92-0.93)	<0.001
Prior cerebrovascular accident	0.83 (0.80-0.86)	<0.001	0.81 (0.80-0.82)	<0.001	1.08 (1.05-1.11)	<0.001	2.26 (2.21-2.30)	<0.001	0.91 (0.90-0.92)	<0.001
Renal failure	1.09 (1.06-1.11)	<0.001	0.92 (0.90-0.93)	< 0.001	1.53 (1.50-1.57)	<0.001	0.64 (0.63-0.65)	<0.001	3.37 (3.32-3.42)	<0.001
Liver disease	2.43 (1.36-2.59)	<0.001	1.07 (0.05-1.09)	< 0.001	1.19 (1.15-1.23)	<0.001	0.60 (0.58-0.62)	<0.001	1.69 (1.66-1.71)	<0.001
Coagulopathy	2.02 (1.97-2.08)	<0.001	1.23 (1.20-1.25)	< 0.001	0.94 (0.91-0.97)	<0.001	0.89 (0.86-0.91)	<0.001	1.80 (1.78-1.83)	<0.001

Thrombophilia	0.95 (0.93-0.97)	<0.001	0.99 (0.99-1.00)	0.638	0.99 (0.98-1.01)	0.49	1.23 (1.21-1.25)	<0.001	0.95 (0.95-0.96)	<0.001
AIDS/HIV	1.05 (0.92-1.20)	0.49	0.91 (0.84-0.99)	0.036	1.10 (0.95-1.27)	0.22	1.02 (0.91-1.14)	0.71	1.44 (1.38-1.50)	<0.001
Rheumatoid arthritis	0.84 (0.79-0.89)	<0.001	0.92 (0.90-0.95)	< 0.001	1.03 (0.99-1.08)	0.18	0.81 (0.78-084)	<0.001	1.05 (1.03-1.06)	<0.001
Blood loss anemia	0.77 (0.70-0.85)	<0.001	0.74 (0.70-0.78)	< 0.001	1.14 (1.04-1.25)	<0.001	0.51 (0.47-0.55)	<0.001	1.05 (1.02-1.08)	<0.001
Deficiency anemia	0.73 (0.70-0.77)	<0.001	0.81 (0.79-0.83)	<0.001	1.38 )1.33-1.43)	<0.001	0.65 (0.63-0.67)	<0.001	1.33 (1.31-1.35)	<0.001
Solid tumor without metastasis	0.97 (0.92-1.01)	0.13	0.70 (0.68-0.72)	<0.001	0.88 (0.84-0.92)	<0.001	0.68 (0.66-0.70)	<0.001	1.09 (1.07-1.10)	<0.001
Metastatic cancer	1.13 (1.07-1.20)	<0.001	0.78 (0.75-0.81)	<0.001	0.88 (0.83-0.93)	<0.001	0.95 (0.92-0.99)	0.22	1.22 (1.20-1.24)	<0.001
Lymphoma	0.80 (0.74-0.88)	<0.001	0.63 (0.60-0.66)	<0.001	0.93 (0.87-0.99)	0.04	0.56 (0.52-0.60)	<0.001	1.25 (1.22-1.28)	<0.001

Abbreviations: OR: Odds Ratio; 95%CI: Confidence interval




Figure 1: Forest plot depicting the unadjusted and adjusted odds ratio and 95% confidence interval for all the outcomes.